Clairity, Myriad Genetics, and MagView have announced a new collaboration designed to help identify more women at high risk for breast cancer. The initiative aims to close a longstanding gap in breast cancer risk assessment while avoiding added administrative burden for healthcare providers.
This partnership brings together three major leaders in breast health:
Clairity – creator of Clairity Breast, the first and only FDA-authorized technology that can estimate a woman’s five-year breast cancer risk directly from a routine mammogram.
Myriad Genetics – a prominent name in molecular diagnostics and precision medicine, offering the MyRisk® Hereditary Cancer Test with RiskScore®, which combines genetic information, clinical factors (Tyrer-Cuzick), and polygenic risk.
MagView – a leading provider of comprehensive software solutions for breast imaging centers.
For the first time, clinicians and patients will be able to access integrated genotype data (through Myriad’s MyRisk with RiskScore) and phenotype information (through Clairity Breast) within MagView’s Luminary Risk platform, which supports breast cancer risk assessment programs across the United States.
“By integrating directly with MagView alongside Myriad, we are giving clinicians a more complete and actionable view of risk than can be achieved using age and family history alone,” said Jeff Luber, CEO, Clairity. “Using AI-powered risk assessment, Clairity Breast identifies women at the highest risk from a routine mammogram.”
“Effective screening of individuals with elevated risk of cancer is an important part of the cancer care continuum,” said Sam Raha, President and CEO, Myriad Genetics. “By pairing the MyRisk Hereditary Cancer Test with Clairity’s AI-powered risk assessment within MagView’s workflow, we aim to empower clinicians with actionable results, helping to enable earlier, more personalized interventions in the fight against breast cancer.”
“Our platform streamlines how risk information is captured, interpreted, and acted on,” said Bryan Chapin, President and CEO, MagView. “Integrating Clairity and MyRisk into one platform gives providers a powerful, unified tool to support proactive breast health management, while improving workflow efficiency.”
Read More